argenx (ARGX) vs BeOne Medicines (ONC)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 7, 2026.
Summary
argenx (ARGX) has outperformed BeOne Medicines (ONC) over the past year, gaining 16.4% versus a gain of 6.6%. Over five years, ARGX leads with a +216.2% price change compared with +1.6% for ONC. argenx is the larger company by market cap ($57.74 billion vs $41.41 billion), about 1.4 times the size.
On valuation, argenx trades at a lower forward P/E (26.7x vs 35.5x for BeOne Medicines).
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARGX | ONC |
|---|---|---|
| Share price | $928.44 | $364.02 |
| Market cap | $57.74B | $41.41B |
| 1-day change | -0.22% | +0.34% |
| YTD return | +10.40% | +19.82% |
| 1-year return | +16.44% | +6.56% |
| 5-year return | +216.24% | +1.56% |
| P/E ratio (TTM) | 35.38 | 65.12 |
| Forward P/E | 26.74 | 35.49 |
| EPS (TTM) | $26.24 | $5.59 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $5.34B |
| Revenue growth (YoY) | — | +40.23% |
| Net income (latest FY) | $1.29B | $286.93M |
| Gross margin | — | 87.49% |
| Operating margin | — | 8.37% |
| Net margin | — | 5.37% |
| 52-week high | $1,072.75 | $385.22 |
| 52-week low | $661.85 | $253.95 |
| Distance from 52-week high | -13.45% | -5.50% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +27.12% | +19.55% |
| Average volume | 283.20K | 391.40K |
| Shares outstanding | 62.19M | 104.92M |
| Employees | 1,863 | 12,000 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BeOne Medicines trades at a higher earnings multiple (65.1x vs 35.4x trailing P/E).
About argenx
ARGX stock →argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases in the United States, Japan, China, the Netherlands, and internationally. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP).
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 1,863 employees
About BeOne Medicines
ONC stock →BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors.
Health Care · Biotechnology: Pharmaceutical Preparations · 12,000 employees
ARGX vs ONC FAQ
Which is bigger, argenx or BeOne Medicines?
argenx (ARGX) is larger, with a market capitalization of $57.74B compared with $41.41B for BeOne Medicines (ONC).
Which stock has performed better over the past year, ARGX or ONC?
ARGX returned +16.44% over the past 12 months, compared with +6.56% for ONC (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, ARGX or ONC?
ARGX has the lower trailing P/E at 35.4, versus 65.1 for ONC. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are argenx and BeOne Medicines in the same industry?
Both are in the Health Care sector, but in different industries: Biotechnology: Biological Products (No Diagnostic Substances) for argenx and Biotechnology: Pharmaceutical Preparations for BeOne Medicines.